1
|
Naghavi M, Atlas K, Reeves A, Zhang C, Wasserthal J, Atlas T, Henschke CI, Yankelevitz DF, Zulueta JJ, Budoff MJ, Branch AD, Ma N, Yip R, Fan W, Roy SK, Nasir K, Molloi S, Fayad Z, McConnell MV, Kakadiaris I, Maron DJ, Narula J, Williams K, Shah PK, Abela G, Vliegenthart R, Levy D, Wong ND. AI-enabled opportunistic measurement of liver steatosis in coronary artery calcium scans predicts cardiovascular events and all-cause mortality: an AI-CVD study within the Multi-Ethnic Study of Atherosclerosis (MESA). BMJ Open Diabetes Res Care 2025; 13:e004760. [PMID: 40221147 PMCID: PMC11997824 DOI: 10.1136/bmjdrc-2024-004760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/15/2024] [Accepted: 03/06/2025] [Indexed: 04/14/2025] Open
Abstract
INTRODUCTION About one-third of adults in the USA have some grade of hepatic steatosis. Coronary artery calcium (CAC) scans contain more information than currently reported. We previously reported new artificial intelligence (AI) algorithms applied to CAC scans for opportunistic measurement of bone mineral density, cardiac chamber volumes, left ventricular mass, and other imaging biomarkers collectively referred to as AI-cardiovascular disease (CVD). In this study, we investigate a new AI-CVD algorithm for opportunistic measurement of liver steatosis. METHODS We applied AI-CVD to CAC scans from 5702 asymptomatic individuals (52% female, age 62±10 years) in the Multi-Ethnic Study of Atherosclerosis. Liver attenuation index (LAI) was measured using the percentage of voxels below 40 Hounsfield units. We used Cox proportional hazards regression to examine the association of LAI with incident CVD and mortality over 15 years, adjusted for CVD risk factors and the Agatston CAC score. RESULTS A total of 751 CVD and 1343 deaths accrued over 15 years. Mean±SD LAI in females and males was 38±15% and 43±13%, respectively. Participants in the highest versus lowest quartile of LAI had greater incidence of CVD over 15 years: 19% (95% CI 17% to 22%) vs 12% (10% to 14%), respectively, p<0.0001. Individuals in the highest quartile of LAI (Q4) had a higher risk of CVD (HR 1.43, 95% CI 1.08 to 1.89), stroke (HR 1.77, 95% CI 1.09 to 2.88), and all-cause mortality (HR 1.36, 95% CI 1.10 to 1.67) compared with those in the lowest quartile (Q1), independent of CVD risk factors. CONCLUSION AI-enabled liver steatosis measurement in CAC scans provides opportunistic and actionable information for early detection of individuals at elevated risk of CVD events and mortality, without additional radiation.
Collapse
Affiliation(s)
| | - Kyle Atlas
- HeartLung Technologies, Houston, Texas, USA
| | | | | | | | | | | | | | | | | | | | - Ning Ma
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Rowena Yip
- Mount Sinai Medical Center, New York, New York, USA
| | - Wenjun Fan
- University of California, Irvine, California, USA
| | - Sion K Roy
- The Lundquist Institute, Torrance, California, USA
| | | | - Sabee Molloi
- University of California, Irvine, California, USA
| | - Zahi Fayad
- Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | | | | | - David J Maron
- Stanford University School of Medicine, Stanford, California, USA
| | - Jagat Narula
- The University of Texas Health Science Center at Houston, Houston, Texas, USA
| | - Kim Williams
- University of Louisville, Louisville, Kentucky, USA
| | | | - George Abela
- Michigan State University, East Lansing, Michigan, USA
| | | | - Daniel Levy
- National Institutes of Health, Bethesda, Maryland, USA
| | | |
Collapse
|
2
|
Zhou Y, Liu J. The role of lipoprotein sulfatides in MASLD fibrosis transition: A new frontier in hepatic immunomodulation. Metabol Open 2025; 25:100335. [PMID: 40176831 PMCID: PMC11963198 DOI: 10.1016/j.metop.2024.100335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2024] [Accepted: 11/27/2024] [Indexed: 04/04/2025] Open
Affiliation(s)
- Yifan Zhou
- Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, Beijing, 100101, China
- University of Chinese Academy of Sciences, Beijing, 100049, China
| | - Junli Liu
- Shanghai Diabetes Institute, Department of Endocrinology and Metabolism, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
| |
Collapse
|
3
|
Ye J, Yin J. Type 2 diabetes: a sacrifice program handling energy surplus. LIFE METABOLISM 2024; 3:loae033. [PMID: 39873003 PMCID: PMC11748514 DOI: 10.1093/lifemeta/loae033] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 03/29/2024] [Revised: 07/30/2024] [Accepted: 09/12/2024] [Indexed: 01/30/2025]
Abstract
Type 2 diabetes mellitus (T2DM) is closely associated with obesity, while interactions between the two diseases remain to be fully elucidated. To this point, we offer this perspective to introduce a set of new insights into the interpretation of T2DM spanning the etiology, pathogenesis, and treatment approaches. These include a definition of T2DM as an energy surplus-induced diabetes characterized by the gradual decline of β cell insulin secretion function, which ultimately aims to prevent the onset of severe obesity through mechanisms of weight loss. The body employs three adaptive strategies in response to energy surplus: the first one is adipose tissue expansion to store the energy for weight gain under normal weight conditions; the second one is insulin resistance to slow down adipose tissue expansion and weight gain under overweight conditions; and the third one is the onset of T2DM following β cell failure to reverse the weight gain in obese conditions. The primary signaling molecules driving the compensatory responses are adenosine derivatives, such as adenosine triphosphate (ATP), acetyl coenzyme A (acetyl-CoA), and reduced nicotinamide adenine dinucleotide (NADH). These molecules exert their effects through allosteric, post-translational, and transcriptional regulation of metabolic pathways. The insights suggest that insulin resistance and T2DM are protective mechanisms in the defense against excessive adiposity to avert severe obesity. The perspective provides a unified framework explaining the interactions between the two diseases and opens new avenues in the study of T2DM.
Collapse
Affiliation(s)
- Jianping Ye
- Metabolic Disease Research Center, Zhengzhou Key Laboratory of Obesity Research, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450007, China
- Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, Henan 450052, China
| | - Jun Yin
- Department of Endocrinology and Metabolism, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Clinical Center for Diabetes, Shanghai Diabetes Institute, Shanghai Key Laboratory of Diabetes Mellitus, Shanghai 200233, China
| |
Collapse
|
4
|
Sharma N, Singh L, Sharma A, Kumar A, Mahajan D. NAFLD-associated hepatocellular carcinoma (HCC) - A compelling case for repositioning of existing mTORc1 inhibitors. Pharmacol Res 2024; 208:107375. [PMID: 39209081 DOI: 10.1016/j.phrs.2024.107375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2024] [Revised: 08/06/2024] [Accepted: 08/23/2024] [Indexed: 09/04/2024]
Abstract
The increasing prevalence of non-alcoholic fatty liver disease (NAFLD) is a growing concern for the high incidence rate of hepatocellular carcinoma (HCC) globally. The progression of NAFLD to HCC is heterogeneous and non-linear, involving intermediate stages of non-alcoholic steatohepatitis (NASH), liver fibrosis, and cirrhosis. There is a high unmet clinical need for appropriate diagnostic, prognostic, and therapeutic options to tackle this emerging epidemic. Unfortunately, at present, there is no validated marker to identify the risk of developing HCC in patients suffering from NAFLD or NASH. Additionally, the current treatment protocols for HCC don't differentiate between viral infection or NAFLD-specific etiology of the HCC and have a limited success rate. The mammalian target of rapamycin complex 1 (mTORc1) is an important protein involved in many vital cellular processes like lipid metabolism, glucose homeostasis, and inflammation. These cellular processes are highly implicated in NAFLD and its progression to severe liver manifestations. Additionally, hyperactivation of mTORc1 is known to promote cell proliferation, which can contribute to the genesis and progression of tumors. Many mTORc1 inhibitors are being evaluated for different types of cancers under various phases of clinical trials. This paper deliberates on the strong pathological implication of the mTORc1 signaling pathway in NAFLD and its progression to NASH and HCC and advocates for a systematic investigation of known mTORc1 inhibitors in suitable pre-clinical models of HCC having NAFLD/NASH-specific etiology.
Collapse
Affiliation(s)
- Nutan Sharma
- Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India; Department of Chemistry, Faculty of Applied and Basic Sciences, SGT University, Gurugram 122505, India
| | - Lakhwinder Singh
- Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India
| | - Aditya Sharma
- Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India
| | - Ajay Kumar
- Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India
| | - Dinesh Mahajan
- Center for Drug Discovery, BRIC-Translational Health Science and Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad 121001, India.
| |
Collapse
|
5
|
Qi Y, Liu X, Chen Y, Wu Y, Sun Y, Liu X, Bao Q, Zhang J, Yuan G, Wang T, Sun X, Liu S, Gao H. Enhanced Intrusion of Exogenous Airborne Fine Particles toward Eyes in Humans and Animals: Where Damaged Blood-Ocular Barrier Plays a Crucial Role. ENVIRONMENTAL SCIENCE & TECHNOLOGY 2024; 58:13636-13647. [PMID: 38961559 PMCID: PMC11308520 DOI: 10.1021/acs.est.4c01791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/20/2024] [Revised: 06/27/2024] [Accepted: 06/28/2024] [Indexed: 07/05/2024]
Abstract
Emerging data suggest a close correlation between ambient fine particle (AFP) exposure and eye disorders and pinpoint potential threats of AFPs to eye health in humans. However, the possible passage (including direct intrusion) and the interactions of AFPs with the eye microenvironment in addition to morphological and physiological injuries remain elusive. To this end, the likely transport of AFPs into the eyes via blood-ocular barrier (BOB) in humans and animals was investigated herein. Exogenous particles were recognized inside human eyes with detailed structural and chemical fingerprints. Importantly, comparable AFPs were found in sera with constant structural and chemical fingerprints, hinting at the translocation pathway from blood circulation into the eye. Furthermore, we found that the particle concentrations in human eyes from patients with diabetic retinopathy were much higher than those from patients with no fundus pathological changes (i.e., myopia), indicating that the damaged BOB increased the possibility of particle entrance. Our diseased animal model further corroborated these findings. Collectively, our results offer a new piece of evidence on the intrusion of exogenous particles into human eyes and provide an explanation for AFP-induced eye disorders, with substantially increased risk in susceptible individuals with BOB injuries.
Collapse
Affiliation(s)
- Yu Qi
- State
Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese
Academy of Sciences, Beijing 100085, China
- College
of Resources and Environment, University
of Chinese Academy of Sciences, Beijing 100049, China
| | - Xiaoxue Liu
- State
Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory
of Ophthalmology, Eye Institute of Shandong
First Medical University, Eye Hospital of Shandong First Medical University, Qingdao 266000, China
- School
of Ophthalmology, Shandong First Medical
University & Shandong Academy of Medical Science, Jinan 250000, China
- Science
and Technology Innovation Center, Shandong
First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China
| | - Yucai Chen
- State
Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese
Academy of Sciences, Beijing 100085, China
- College
of Resources and Environment, University
of Chinese Academy of Sciences, Beijing 100049, China
| | - Yue Wu
- State
Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese
Academy of Sciences, Beijing 100085, China
- College
of Resources and Environment, University
of Chinese Academy of Sciences, Beijing 100049, China
| | - Yu Sun
- State
Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory
of Ophthalmology, Eye Institute of Shandong
First Medical University, Eye Hospital of Shandong First Medical University, Qingdao 266000, China
| | - Xiaoyu Liu
- State
Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory
of Ophthalmology, Eye Institute of Shandong
First Medical University, Eye Hospital of Shandong First Medical University, Qingdao 266000, China
| | - Qingdong Bao
- State
Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory
of Ophthalmology, Eye Institute of Shandong
First Medical University, Eye Hospital of Shandong First Medical University, Qingdao 266000, China
| | - Jingjing Zhang
- State
Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory
of Ophthalmology, Eye Institute of Shandong
First Medical University, Eye Hospital of Shandong First Medical University, Qingdao 266000, China
| | - Gongqiang Yuan
- State
Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory
of Ophthalmology, Eye Institute of Shandong
First Medical University, Eye Hospital of Shandong First Medical University, Qingdao 266000, China
| | - Ting Wang
- State
Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory
of Ophthalmology, Eye Institute of Shandong
First Medical University, Eye Hospital of Shandong First Medical University, Qingdao 266000, China
| | - Xiaolei Sun
- State
Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory
of Ophthalmology, Eye Institute of Shandong
First Medical University, Eye Hospital of Shandong First Medical University, Qingdao 266000, China
| | - Sijin Liu
- State
Key Laboratory of Environmental Chemistry and Ecotoxicology, Research Center for Eco-Environmental Sciences, Chinese
Academy of Sciences, Beijing 100085, China
- College
of Resources and Environment, University
of Chinese Academy of Sciences, Beijing 100049, China
- Science
and Technology Innovation Center, Shandong
First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China
| | - Hua Gao
- State
Key Laboratory Cultivation Base, Shandong Provincial Key Laboratory
of Ophthalmology, Eye Institute of Shandong
First Medical University, Eye Hospital of Shandong First Medical University, Qingdao 266000, China
- School
of Ophthalmology, Shandong First Medical
University & Shandong Academy of Medical Science, Jinan 250000, China
- Science
and Technology Innovation Center, Shandong
First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China
| |
Collapse
|
6
|
Luo W, Xiao Z, Yang X, Wu R, Li J, Yu Z, Guo S, Nie B, Liu D. Liver fat as a dietary target by Chinese Medical Nutrition Therapy (CMNT) diet for treating type 2 diabetes with non-alcoholic fatty liver disease: study protocol for a randomised controlled trial. BMJ Open 2024; 14:e081263. [PMID: 38684277 PMCID: PMC11086286 DOI: 10.1136/bmjopen-2023-081263] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Accepted: 04/10/2024] [Indexed: 05/02/2024] Open
Abstract
INTRODUCTION Type 2 diabetes and non-alcoholic fatty liver disease (NAFLD) often coexist and increase risk for developing liver fibrosis and diabetes complications if no effective measures are taken. Dietary intervention is known to be able to achieve diabetes remission, while evidence regarding the long-term effect on liver fat is limited for comorbidity management of type 2 diabetes and NAFLD. This study aims to investigate the long-term effect of a Chinese Medical Nutrition Therapy (CMNT) diet accompanied by intermittent energy restriction on reducing liver fat and glycated haemoglobin (HbA1c) in patients with type 2 diabetes and NAFLD. METHODS AND ANALYSIS This is a multicentre two-armed parallel randomised controlled trial study. 120 participants with type 2 diabetes and NAFLD will be recruited from the physical examination centres of multiple hospitals in China. Participants will be randomly allocated 1:1 to either the CMNT group or the usual care group. The CMNT group will be instructed to consume the provided specific meal replacement Chinese medicinal foods consisting of 6 cycles of 5 consecutive days followed by 10 days of regular food intake. The usual care group will be given standard dietary advice. Primary outcomes are changes in the controlled attenuation parameter value by transient elastography and HbA1c level. Secondary outcomes include differences in anthropometrics, clinical blood markers, questionnaires, gut microbiota and metabolomics. Further follow-up will be performed at 6 months, 1 year and 2 years. ETHICS AND DISSEMINATION The study protocol was approved by the Biomedical Research Ethics Committee of Hunan Agricultural University (BRECHAU20200235).The results will be disseminated via relevant peer-reviewed publications and conference presentations. TRIAL REGISTRATION NUMBER NCT05439226.
Collapse
Affiliation(s)
- Wu Luo
- College of Biology, Hunan University, Changsha, Hunan, China
- Horticulture College, Hunan Agricultural University, Changsha, Hunan, China
| | - Zhiyong Xiao
- Horticulture College, Hunan Agricultural University, Changsha, Hunan, China
- The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China
| | - Xiao Yang
- Horticulture College, Hunan Agricultural University, Changsha, Hunan, China
- Hunan Provincial Engineering Research Center of Medical Nutrition Intervention Technology for Metabolic Diseases, Changsha, Hunan, China
| | - Ruiyu Wu
- Horticulture College, Hunan Agricultural University, Changsha, Hunan, China
- Hunan Provincial Engineering Research Center of Medical Nutrition Intervention Technology for Metabolic Diseases, Changsha, Hunan, China
| | - Jian Li
- Hunan Provincial Engineering Research Center of Medical Nutrition Intervention Technology for Metabolic Diseases, Changsha, Hunan, China
- Clinical Research Centre, State Key Laboratory of Subhealth Intervention Technology, Changsha, Hunan, China
| | - Zhen Yu
- Horticulture College, Hunan Agricultural University, Changsha, Hunan, China
| | - Shengxiang Guo
- Horticulture College, Hunan Agricultural University, Changsha, Hunan, China
| | - Beibei Nie
- Horticulture College, Hunan Agricultural University, Changsha, Hunan, China
| | - Dongbo Liu
- Horticulture College, Hunan Agricultural University, Changsha, Hunan, China
- Clinical Research Centre, State Key Laboratory of Subhealth Intervention Technology, Changsha, Hunan, China
| |
Collapse
|
7
|
Kaur M, Murugesan S, Singh S, Uy KN, Kaur J, Mann N, Sekhon RK. The Influence of Coffee on Reducing Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes: A Review. Cureus 2023; 15:e50118. [PMID: 38192918 PMCID: PMC10772480 DOI: 10.7759/cureus.50118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/07/2023] [Indexed: 01/10/2024] Open
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a liver disease characterized by hepatic fat accumulation associated with various severities of inflammation and scarring. As studies explore specialized treatments, emerging evidence suggests a potential protective effect of coffee consumption. Consumption of coffee or its components, such as caffeine and/or chlorogenic acid (CA), can reduce markers of liver injury and induce a myriad of other health benefits. However, there is limited research on patients with both MASLD and type 2 diabetes (T2D). Current research suggests that patients with MASLD are at greater risk of developing T2D and future liver-related complications and vice versa. Given that both MASLD and T2D are global burdens, the present literature review analyzes current research to identify trends and determine if coffee can be a viable treatment for MASLD patients with T2D. Results indicate that coffee consumption may protect against MASLD in T2D patients who are overweight/obese through a declined rate of weight gain, inhibition of the mammalian target of rapamycin (mTOR) gene, and insignificant changes to the gut microbiome. More longitudinal research on human subjects is needed to establish a causal relationship between coffee consumption and MASLD alleviation.
Collapse
Affiliation(s)
- Manpreet Kaur
- Medicine, University of California, Davis, Davis, USA
| | | | | | | | - Jasjeet Kaur
- Medicine, University of California, Davis, Davis, USA
| | - Navina Mann
- Medicine, University of California, Davis, Davis, USA
| | | |
Collapse
|
8
|
Guo S, Feng Y, Zhu X, Zhang X, Wang H, Wang R, Zhang Q, Li Y, Ren Y, Gao X, Bian H, Liu T, Gao H, Kong X. Metabolic crosstalk between skeletal muscle cells and liver through IRF4-FSTL1 in nonalcoholic steatohepatitis. Nat Commun 2023; 14:6047. [PMID: 37770480 PMCID: PMC10539336 DOI: 10.1038/s41467-023-41832-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2022] [Accepted: 09/19/2023] [Indexed: 09/30/2023] Open
Abstract
Inter-organ crosstalk has gained increasing attention in recent times; however, the underlying mechanisms remain unclear. In this study, we elucidate an endocrine pathway that is regulated by skeletal muscle interferon regulatory factor (IRF) 4, which manipulates liver pathology. Skeletal muscle specific IRF4 knockout (F4MKO) mice exhibited ameliorated hepatic steatosis, inflammation, and fibrosis, without changes in body weight, when put on a nonalcoholic steatohepatitis (NASH) diet. Proteomics analysis results suggested that follistatin-like protein 1 (FSTL1) may constitute a link between muscles and the liver. Dual luciferase assays showed that IRF4 can transcriptionally regulate FSTL1. Further, inducing FSTL1 expression in the muscles of F4MKO mice is sufficient to restore liver pathology. In addition, co-culture experiments confirmed that FSTL1 plays a distinct role in various liver cell types via different receptors. Finally, we observed that the serum FSTL1 level is positively correlated with NASH progression in humans. These data indicate a signaling pathway involving IRF4-FSTL1-DIP2A/CD14, that links skeletal muscle cells to the liver in the pathogenesis of NASH.
Collapse
Affiliation(s)
- Shanshan Guo
- Department of Endocrinology and Metabolism, State Key Laboratory of Genetic Engineering, School of Life Sciences, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Yonghao Feng
- Department of Endocrinology and Metabolism, State Key Laboratory of Genetic Engineering, School of Life Sciences, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Xiaopeng Zhu
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
| | - Xinyi Zhang
- Human Phenome Institute, Fudan University, Shanghai, 201203, China
| | - Hui Wang
- Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism & Integrative Biology, Fudan University, Shanghai, 200438, China
| | - Ruwen Wang
- School of Kinesiology, Shanghai University of Sport, Shanghai, 200438, China
| | - Qiongyue Zhang
- Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Yiming Li
- Department of Endocrinology and Metabolism, Huashan Hospital, Fudan University, Shanghai, 200040, China
| | - Yan Ren
- Experiment Center for Science and Technology, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China
| | - Xin Gao
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China
| | - Hua Bian
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
| | - Tiemin Liu
- Department of Endocrinology and Metabolism, State Key Laboratory of Genetic Engineering, School of Life Sciences, Huashan Hospital, Fudan University, Shanghai, 200040, China.
- Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
- Human Phenome Institute, Fudan University, Shanghai, 201203, China.
- Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism & Integrative Biology, Fudan University, Shanghai, 200438, China.
| | - Huanqing Gao
- Department of Endocrinology and Metabolism, State Key Laboratory of Genetic Engineering, School of Life Sciences, Huashan Hospital, Fudan University, Shanghai, 200040, China.
| | - Xingxing Kong
- Department of Endocrinology and Metabolism, State Key Laboratory of Genetic Engineering, School of Life Sciences, Huashan Hospital, Fudan University, Shanghai, 200040, China.
- Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism & Integrative Biology, Fudan University, Shanghai, 200438, China.
| |
Collapse
|